Results 31 to 40 of about 143,596 (340)
PLoS ONE, 2019 Stroke patients are at high risk of developing pneumonia, which is major cause of post-stroke mortality. Proton pump inhibitors and H2 receptor antagonists are anti-ulcer drugs, which may predispose to the development of pneumonia by suppression of the ...
Tae-Jin Song, Jinkwon Kim
doaj +1 more source
The impact of drug-drug interactions between proton pump inhibitors and metformin: A systematic review of clinical evidence [PDF]
PharmaciaMetformin, a substrate of the organic cation transporters, is commonly co-prescribed with proton pump inhibitors, which inhibits these transporters. However, the clinical significance of this potential drug-drug interaction remains unclear.
Ria Andani Antong +3 more
doaj +3 more sources
Use of proton pump inhibitors in adults in France: a nationwide drug utilization study
European Journal of Clinical Pharmacology, 2019 Proton pump inhibitor (PPI) drugs are approved for the management of gastric acid–related diseases, mainly treatment of gastroesophageal reflux disease, treatment of nonsteroidal anti-inflammatory drugs (NSAID)–related gastrointestinal complications and ...
Marion Lassalle +8 more
semanticscholar +1 more source
Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors
eJHaem, 2020 Background Iron deficiency anemia without evidence for blood loss can present a diagnostic challenge. Proton pump inhibitors have been associated with iron deficiency anemia for many years, yet the relationship between the two until recently was not ...
Michael Boxer
doaj +1 more source
Systematic review with meta‐analysis: the risks of proton pump inhibitors during pregnancy
Alimentary Pharmacology and Therapeutics, 2020 There have been safety concerns considering long‐term proton pump inhibitor (PPI) use, also during pregnancy.
C. Li +4 more
semanticscholar +1 more source
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study
Pharmacotherapy, 2019 Proton pump inhibitors (PPIs) have been linked to acute kidney injury (AKI) and chronic kidney disease (CKD); however, current evidence has only been evaluated in a small number of studies with short follow‐up periods. This study examined the association
E. Hart +3 more
semanticscholar +1 more source
Лечащий Врач, 2021 Proton pump inhibitors are a diverse class of drugs with unique acid suppression properties. The aim of the work was to present the therapeutic benefits of rabeprazole and pantoprazole in clinical practice.
E. A. Lyalukova +3 more
doaj +1 more source
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
Expert Opinion on Drug Metabolism & Toxicology, 2018 Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This
Nihal El Rouby +2 more
semanticscholar +1 more source
Proton pump inhibitors overuse - consequences among patients
Journal of Education, Health and Sport, 2019 Introduction Omeprazole was first proton pump inhibitor (PPI) approved for use by patients. Thirty years have passed since then. Due to their effectiveness, low price and safety proton pump inhibitors have become one of the most frequently prescribed ...
Patrycja Kmiotek +2 more
doaj +3 more sources
Dermatology Practical & Conceptual, 2015 Background: Sweet’s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug.
Philip R. Cohen
doaj +1 more source